Reviewed by Michael Gill, B. Sc.
Image of Station 5 in Milwaukee, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Corrective Exercise Programfor Functional Movement Quality

18+
All Sexes
The occupation of firefighting is considered to be one of the most dangerous occupations in the United States (U.S.). As such, a high prevalence of musculoskeletal injuries (MSKIs) have been observed among the firefighter population. This high rate of MSKI has created an extremely large financial impact on fire departments across the United States. Therefore, interest in developing methods of identifying those at risk for developing a future MSKI and interventions designed to prevent these MSKIs from happening has grown among both the firefighter population, as well as among researchers and practitioners. Previous research has demonstrated relationships between MSKI and altered movement patterns. In addition, researchers have started to demonstrate the ability of functional movement assessments to predict future MSKI in various populations, including firefighters. Two of these functional movement assessments include the Functional Movement Screen (FMS) and the Movement Efficiency (ME) Test, which is a component of the Fusionetics Human Performance System. These assessments both quantify the overall functional movement quality of an individual by creating a composite movement score (i.e., Total FMS & Average ME Test scores, respectively). In addition, various theoretical models of corrective exercise programming have been proposed. These programs are designed to restore optimal neuromuscular control and correct any identified neuromuscular imbalances observed during the movement assessment through the use of simple and easy-to-follow exercises. The Fusionetics Human Performance System utilizes one such model, with the goal of improving the functional movement quality of an individual by correcting the aforementioned neuromuscular deficiencies observed during the ME Test. Based on this framework, these corrective exercise programs theoretically lower the risk of MSKI of the individual as well. However, there is currently a lack of research in the literature examining the influence of corrective exercise programming on functional movement quality among the active-duty firefighter population. As such, it remains unknown if a corrective exercise intervention is capable of significantly improving functional movement quality among active-duty firefighters. In addition, recent research suggests that various health and fitness measures are associated with functional movement quality. These measures include total body power output, lower extremity muscular strength, and core muscular endurance. As such, an examination of the influence of a corrective exercise intervention on measures of health and fitness among active-duty firefighters is warranted.
Waitlist Available
Has No Placebo
Station 5Kyle T. Ebersole, Ph.D.
Image of Stony Brook Hospital in Stony Brook, United States.
Phase-Based Progress Estimates
3
Effectiveness
3
Safety

Group Afor Flu caused by Influenza

18+
All Sexes
Seasonal influenza (flu) is a significant and sometimes serious health issue in the U.S. The Centers for Disease Control (CDC) estimates that over 200,000 people are hospitalized in the U.S each year related to the flu. Public health campaigns advocate widespread vaccination for the flu, and especially for high risk people. People with cancer are high risk, with an increased risk of developing complications from the flu, such as pneumonia, bronchitis, or worsening of other medical conditions. As part of their vaccination campaign, the CDC strongly encourages inpatients to be vaccinated prior to hospital discharge. Accordingly, Stony Brook Hospital has enacted a policy that mandates screening all hospital inpatients for vaccination prior to discharge. While physicians or patients can opt not to vaccinate, the default is to proceed. Surgical oncologists have several concerns about vaccinating their patients after major surgical procedures. Patients with cancer have impaired immunity, and the ability of our patients to mount an effective immune response to the vaccine is unclear. Conversely, due to their immunocompromised state, our patients may be more susceptible to complications from the vaccine, such as influenza-like-illness (ILI), or have higher rates of postoperative complications due to the additional immune challenge of the vaccine. Previous studies have evaluated the flu vaccine in patients receiving chemotherapy, or after organ transplantation, but the combination of cancer and major surgery remains unstudied. This is a collaborative study with Infectious Diseases and Microbiology to evaluate the response to the flu vaccine in patients with pancreatic or gastric cancer, soft tissue sarcoma or peritoneal surface disease (i.e. carcinomatosis from appendiceal or colon cancers). Patients will be randomly selected to receive the vaccine either 2 weeks preoperatively or postoperatively at the time of discharge. Serum antibody response, rates of ILI and post-op complications will be analyzed. The long term goal of this study is two-fold: to determine the optimal time to vaccinate this group of patients in relation to their surgery, and to improve compliance with vaccination.
Phase 4
Waitlist Available
Stony Brook HospitalColette R Pameijer, MD
25 Flu Clinical Trials Near Me
Top Hospitals for Flu Clinical Trials
Image of NYU Langone Health in New York.
NYU Langone Health
New York
6Active Trials
3All Time Trials for Flu
2020First Flu Trial
Top Cities for Flu Clinical Trials
Image of New York in New York.
New York
34Active Trials
NYU Langone HealthTop Active Site
Flu Clinical Trials by Phase of Trial
Phase < 1 Flu Clinical Trials
7Active Flu Clinical Trials
7Number of Unique Treatments
5Number of Active Locations
Treatment Group Live Attenuated Flu Vaccine (LAIV)FluoxetinePET/CT ImagingDiagnostic (fluciclovine F18 PET/CT)[18F]Fluoroestradiol (FES) PET/CTFlucanazoleSilver Diammine Fluoride
Flu Clinical Trials by Age Group
< 18 Flu Clinical Trials
10Active Flu Clinical Trials
Sing2016 M2SR H3N2EpiCorTeriflunomideRIV4 cohortARQ-151 ActiveVaxelisUsual access to sedentary behaviors, Low park accessPhase II: Group B: Study drug (Celecoxib 7 mg/kg)